The historical rank and industry rank for Diagnosticos da America's Net Margin % or its related term are showing as below:
BSP:DASA3'
s Net Margin % Range Over the Past 10 Years
Min: -10.87 Med: -2.16 Max: 4.69
Current: -10.87
BSP:DASA3's Net Margin % is ranked worse than 58.33% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs BSP:DASA3: -10.87
Diagnosticos da America (BSP:DASA3) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Diagnosticos da America Net Margin % Related Terms
Diagnosticos da America Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:DASA3 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Diagnosticos da America's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnosticos da America Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnosticos da America's Net Margin % distribution charts can be found below:
* The bar in red indicates where Diagnosticos da America's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnosticos da America (BSP:DASA3) has a Net Margin % of -0.09% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Diagnosticos da America and its competitors. According to the industry distribution chart, Diagnosticos da America ranks #119 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 58.3%.
Is Diagnosticos da America's Net Margin % too high?
Diagnosticos da America's current Net Margin % is -0.09%. Based on the distribution chart, Diagnosticos da America ranks #119 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnosticos da America ranks #119 out of 204 companies for Net Margin %. This places Diagnosticos da America in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Diagnosticos da America and its competitors. Diagnosticos da America's current Net Margin % is -0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.78 — trading 63.5% above its estimated fair value. The current Net Margin % is -0.09%. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current Net Margin % is -0.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued.
The current stock price of R$2.78 is trading 63.5% above its estimated GF Value™ of R$1.70.
GuruFocus considers Diagnosticos da America to be Significantly Overvalued.
Key valuation signals for BSP:DASA3:
Net Margin %: -0.09%
GF Value™: R$1.70 vs. price of R$2.78 (63.5% above fair value)
No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score
Get the complete analysis for BSP:DASA3
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DASA3 has been successfully added to your 
